CIDP is diagnosed through a combination of clinical evaluation, nerve conduction studies, and supportive tests like spinal fluid analysis. There is no single test that confirms it. Instead, doctors piece together evidence from your symptoms, how long they’ve progressed, electrical tests of your nerves, and sometimes a treatment trial to see if your body responds to immune therapy. The process can take months, partly because symptoms must be present for a minimum duration before the diagnosis applies.
The Timeline That Separates CIDP From GBS
One of the first things a neurologist considers is how long your symptoms have been progressing. Guillain-Barré syndrome (GBS) comes on rapidly, typically reaching its worst point within two to four weeks and often following an infection. CIDP, by contrast, progresses over weeks to months, either continuously or in a stepwise pattern. The current diagnostic guidelines from the European Academy of Neurology and Peripheral Nerve Society require a minimum of one year of symptoms and signs to establish a diagnosis of typical CIDP.
Other features help separate the two conditions. GBS frequently involves cranial nerves (causing facial weakness, difficulty swallowing) and disrupts autonomic functions like heart rate and blood pressure. CIDP rarely does either. If your weakness developed gradually, affects both sides of your body relatively equally, and involves both your arms and legs, the clinical picture points toward CIDP.
Nerve Conduction Studies: The Core Test
Nerve conduction studies (NCS) are the single most important diagnostic test for CIDP. These are electrodiagnostic tests where small electrical impulses are sent through your nerves while sensors measure how fast and how strongly the signals travel. The test is uncomfortable but not dangerous, and it typically takes 30 to 60 minutes.
What doctors are looking for is evidence of demyelination, meaning damage to the insulating coating around your nerves rather than damage to the nerve fibers themselves. Demyelination produces a specific set of abnormalities. Nerve signals travel slower than normal, measured as reduced motor conduction velocity. Signals take longer than expected to reach the end of the nerve, shown as prolonged distal latency. And F-wave responses, which measure signals traveling all the way to the spinal cord and back, arrive late.
To qualify as demyelinating, conduction velocities in the median nerve need to drop below roughly 39 meters per second (normal is 49 or above), and in the leg nerves below about 33 meters per second. Another hallmark finding is conduction block, where a nerve signal loses at least 30% to 50% of its strength between two points along the same nerve. This happens because the signal hits a stretch of damaged myelin and partially stalls out. Abnormal temporal dispersion, where the electrical signal spreads out and becomes smeared as it passes through damaged segments, is also characteristic.
These findings need to appear in multiple nerves. A single abnormal nerve isn’t enough, because localized compression (like carpal tunnel syndrome) can mimic demyelination in one spot.
Spinal Fluid Analysis
A lumbar puncture (spinal tap) provides supporting evidence. The hallmark finding in CIDP is called albuminocytologic dissociation: the protein level in the spinal fluid is elevated, but the white blood cell count stays low. Between 85% and 90% of CIDP patients show this pattern, with fewer than 10 white blood cells per cubic millimeter.
This test matters partly for what it rules out. If the white blood cell count is above 10, your doctor should consider other diagnoses, including infections like HIV or Lyme disease, lymphoma, or sarcoidosis. A normal spinal fluid result doesn’t exclude CIDP, but high protein with low cell counts adds a useful piece to the puzzle.
Antibody Testing
A relatively newer layer of testing looks for specific antibodies that target the junctions where nerve fibers connect to their myelin coating. The most clinically useful is the antibody against a protein called NF155, though antibodies against CNTN1 and CASPR1 are also tested. These antibodies identify a subgroup of CIDP patients who tend to present with tremor and poor balance and, importantly, who respond poorly to standard immunoglobulin therapy.
The NF155 antibody test has high specificity (93%) but lower sensitivity (45%), meaning a positive result is quite reliable, but a negative result doesn’t rule anything out. It functions best as a confirmatory test in patients who aren’t responding to initial treatment. Patients who test positive for NF155 or CNTN1 antibodies may respond better to a different class of immune therapy, so the result can directly change the treatment plan.
Nerve Biopsy: Reserved for Difficult Cases
Nerve biopsy is not routine. It’s an invasive procedure, typically taking a small piece of the sural nerve in the ankle, and it permanently removes sensation from a patch of skin. Doctors reserve it for cases where the diagnosis remains uncertain after other testing, particularly in atypical presentations.
When performed, the defining finding is segmental demyelination: short stretches of myelin are destroyed while the underlying nerve fiber stays intact. Under electron microscopy, immune cells called macrophages can be seen penetrating the cells that produce myelin, actively stripping it away. In a study of 43 biopsies from CIDP patients, 84% showed some degree of nerve fiber loss alongside the demyelination, which helps explain why some patients develop permanent deficits even after treatment. “Onion bulb” formations, where layers of scar tissue build up from repeated cycles of demyelination and attempted repair, appeared in about 19% of cases. Notably, actual inflammatory cell clusters were rare, appearing in under 5% of biopsies, which is why normal-looking inflammation on biopsy doesn’t exclude CIDP.
Treatment Response as Diagnostic Evidence
Because CIDP can be difficult to distinguish from other neuropathies, doctors sometimes use a therapeutic trial as part of the diagnostic process. If your symptoms improve meaningfully after a course of intravenous immunoglobulin (IVIg), that response itself supports the diagnosis.
In clinical studies, improvement was measured by gains in a standardized disability score. Among patients who responded to IVIg, 47% showed measurable improvement by week three, and 53% improved by week six after a second infusion. Grip strength in the dominant hand tended to improve in parallel with or even before broader disability scores, making it a practical early marker you and your doctor can track at home or in the office. If there’s no response after an adequate trial, it doesn’t necessarily exclude CIDP, but it prompts reconsideration of the diagnosis or testing for antibody subtypes that predict poor IVIg response.
Atypical Variants Complicate the Picture
Not everyone with CIDP fits the typical pattern of symmetric weakness in all four limbs. Several recognized variants exist, each with features that can make diagnosis harder.
- MADSAM (Lewis-Sumner syndrome): A painless pattern where demyelination is patchy and asymmetric, affecting individual nerves in different limbs rather than all nerves equally. Conduction blocks tend to cluster in mid-limb or proximal nerve segments.
- DADS: Symptoms start symmetrically in the feet and stay distal, without spreading to proximal muscles or cranial nerves. Nerve conduction studies show disproportionately prolonged distal latencies.
- Pure sensory CIDP: Numbness, tingling, and balance problems without any weakness. Nerve conduction studies still show demyelinating changes in both sensory and motor nerves, even though only sensory symptoms are present clinically.
- Pure motor CIDP: Weakness without sensory symptoms, which can resemble motor neuron disease. The absence of bulbar involvement (no speech or swallowing difficulty) and the presence of demyelinating features on nerve conduction studies help distinguish it.
- Focal CIDP: Affects a single limb, sometimes with visible nerve enlargement. Unlike multifocal motor neuropathy, it includes sensory involvement and responds to steroids.
These variants follow the same general diagnostic framework: clinical pattern plus electrodiagnostic evidence of demyelination plus supportive tests. But because they don’t look like textbook CIDP, they’re more frequently missed or delayed. If your symptoms are asymmetric, purely sensory, or limited to one area, the diagnostic workup may take longer and is more likely to include nerve biopsy or MRI of the spinal roots to look for nerve enlargement.